Literature DB >> 23585659

Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation.

Mary Ellen Pavone1, Serdar E Bulun.   

Abstract

CONTEXT: Anovulation is likely responsible for 20% of female infertility. Although clomiphene citrate remains the first-line therapy for ovulation induction in anovulatory patients who are not estrogen-deficient and to treat unexplained infertility, there remains a discrepancy between ovulation and conception rates with its use, attributed to its antiestrogenic effects on cervical mucus and the endometrium. Alternative agents, including aromatase inhibitors, have been used that have not been associated with these side effects. EVIDENCE ACQUISITION: A literature search was conducted to specifically explore the use of aromatase inhibitors for ovulation induction and superovulation. EVIDENCE SYNTHESIS: Recent studies have found that aromatase inhibitors may be safe and useful agents for ovulation induction in patients with polycystic ovarian syndrome as well a treatment option for superovulation in patients with either unexplained infertility or endometriosis.
CONCLUSIONS: Aromatase inhibitors may be an effective alternative treatment to clomiphene citrate for both ovulation induction and superovulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23585659      PMCID: PMC3644592          DOI: 10.1210/jc.2013-1328

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

Review 1.  Endocrine treatment of breast cancer in women.

Authors:  R J Santen; A Manni; H Harvey; C Redmond
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

2.  A historical perspective of aromatase inhibitors for ovulation induction.

Authors:  Robert F Casper; Mohamed F M Mitwally
Journal:  Fertil Steril       Date:  2012-12       Impact factor: 7.329

3.  Source of estrogen production in postmenopausal women.

Authors:  J M Grodin; P K Siiteri; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

4.  Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.

Authors:  E Bajetta; N Zilembo; E Bichisao; A Martinetti; R Buzzoni; P Pozzi; P Bidoli; L Ferrari; L Celio
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

Review 5.  Aromatase gene expression in adipose tissue: relationship to breast cancer.

Authors:  E R Simpson; M S Mahendroo; J E Nichols; S E Bulun
Journal:  Int J Fertil Menopausal Stud       Date:  1994

Review 6.  Induction of ovulation with clomiphene citrate (clomid).

Authors:  R W Kistner
Journal:  Obstet Gynecol Surv       Date:  1965-12       Impact factor: 2.347

Review 7.  Aromatase gene expression in adipose tissue: relationship to breast cancer.

Authors:  S E Bulun; M S Mahendroo; E R Simpson
Journal:  J Steroid Biochem Mol Biol       Date:  1994-06       Impact factor: 4.292

Review 8.  Ovulatory disorders in women with polycystic ovary syndrome.

Authors:  S Franks; J Adams; H Mason; D Polson
Journal:  Clin Obstet Gynaecol       Date:  1985-09

Review 9.  ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

Authors:  P V Plourde; M Dyroff; M Dowsett; L Demers; R Yates; A Webster
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

10.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

Authors:  J Geisler; N King; M Dowsett; L Ottestad; S Lundgren; P Walton; P O Kormeset; P E Lønning
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more
  12 in total

Review 1.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

2.  Oral Drugs for Unexplained Infertility.

Authors:  Gautam N Allahbadia
Journal:  J Obstet Gynaecol India       Date:  2015-11-13

3.  Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility.

Authors:  Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Joel Ager; Hao Huang; Karl R Hansen; Valerie Baker; Rebecca Usadi; Aimee Seungdamrong; G Wright Bates; R Mitchell Rosen; Daniel Haisenleder; Stephen A Krawetz; Kurt Barnhart; J C Trussell; Dana Ohl; Yufeng Jin; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

Review 4.  Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.

Authors:  Molly B Moravek; Serdar E Bulun
Journal:  Curr Opin Obstet Gynecol       Date:  2015-08       Impact factor: 1.927

Review 5.  Pentoxifylline for the treatment of endometriosis-associated pain and infertility.

Authors:  Alexandros Loukas Grammatis; Ektoras X Georgiou; Christian M Becker
Journal:  Cochrane Database Syst Rev       Date:  2021-08-25

Review 6.  The management of patients with polycystic ovary syndrome.

Authors:  Channa N Jayasena; Stephen Franks
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

7.  Genome-wide Long Non-coding RNA Analysis Identified Circulating LncRNAs as Novel Non-invasive Diagnostic Biomarkers for Gynecological Disease.

Authors:  Wen-Tao Wang; Yu-Meng Sun; Wei Huang; Bo He; Ya-Nan Zhao; Yue-Qin Chen
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

Review 8.  Potential role of aromatase inhibitors in the treatment of endometriosis.

Authors:  Hatem Abu Hashim
Journal:  Int J Womens Health       Date:  2014-07-21

Review 9.  Aromatase inhibitors in the treatment of endometriosis.

Authors:  Radosław Słopień; Błażej Męczekalski
Journal:  Prz Menopauzalny       Date:  2016-03-29

10.  The Estrogen Receptor-β Expression in De Quervain's Disease.

Authors:  Po-Chuan Shen; Ping-Hui Wang; Po-Ting Wu; Kuo-Chen Wu; Jeng-Long Hsieh; I-Ming Jou
Journal:  Int J Mol Sci       Date:  2015-11-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.